Candel Therapeutics (CADL) – Investment Analysts’ Recent Ratings Updates

A number of firms have modified their ratings and price targets on shares of Candel Therapeutics (NASDAQ: CADL) recently:

• 6/1/2026 – Candel Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 5/24/2026 – Candel Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 5/16/2026 – Candel Therapeutics was upgraded by Wall Street Zen from “strong sell” to “hold”.
• 5/15/2026 – Candel Therapeutics was upgraded by Zacks Research from “strong sell” to “hold”.
• 4/20/2026 – Candel Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 4/20/2026 – Candel Therapeutics is now covered by Cantor Fitzgerald. They set an “overweight” rating on the stock.
• 4/7/2026 – Candel Therapeutics was downgraded by Zacks Research from “hold” to “strong sell”.

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.